Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Molecular Transport Inc.
Report date December 27, 2023 · Filed December 29, 2023
Jointly reported with EPIQ Capital Group, LLC, EPQ LLC AMT PS, EPQ LLC, AMTB PS, EPQ LLC, AMTC PS
Section 16 reporting ended · disclosed 2023-12-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Last balance in matching sequence
After 2023-12-27 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2023-12-27 · Other · Disposed 2,149,292 · Balance 6,188,226 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F2: EPQ LLC, AMT PS is the direct owner of these shares. F6: Upon consummation of the Merger, EPQ LLC, AMT PS received Transaction Consideration of 286,071 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Row 2 · 2023-12-27 · Other · Disposed 3,394,948 · Balance 2,793,278 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F3: EPQ LLC, AMTB PS is the direct owner of these shares. F7: Upon consummation of the Merger, EPQ LLC, AMTB PS received Transaction Consideration of 451,868 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Row 3 · 2023-12-27 · Other · Disposed 2,500,000 · Balance 293,278 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F4: EPQ LLC, AMTC PS is the direct owner of these shares. F8: Upon consummation of the Merger, EPQ LLC, AMTC PS received Transaction Consideration of 332,750 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Row 4 · 2023-12-27 · Other · Disposed 293,278 · Balance 0 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F5: Chad Boeding is the owner of these shares through a trust that he controls. F9: Upon consummation of the Merger, Chad Boeding received Transaction Consideration of 39,036 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger.
F2: EPQ LLC, AMT PS is the direct owner of these shares.
F3: EPQ LLC, AMTB PS is the direct owner of these shares.
F4: EPQ LLC, AMTC PS is the direct owner of these shares.
F5: Chad Boeding is the owner of these shares through a trust that he controls.
F6: Upon consummation of the Merger, EPQ LLC, AMT PS received Transaction Consideration of 286,071 shares of Cyclo common stock.
F7: Upon consummation of the Merger, EPQ LLC, AMTB PS received Transaction Consideration of 451,868 shares of Cyclo common stock.
F8: Upon consummation of the Merger, EPQ LLC, AMTC PS received Transaction Consideration of 332,750 shares of Cyclo common stock.
F9: Upon consummation of the Merger, Chad Boeding received Transaction Consideration of 39,036 shares of Cyclo common stock.
F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ.
Lucira Health, Inc.
Report date December 14, 2022 · Filed December 16, 2022
Jointly reported with EPIQ Capital Group, LLC, EPQ LLC, LTEST PS, EPQ LLC, LFLU PS, EPQ LLC, LCOVD PS, EPQ LLC, LCOVD SAFE PS
Section 16 reporting ended · disclosed 2022-12-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,694,761 |
Reported balance
After 2022-12-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-12-14 · Other · Disposed 3,461,764 · Balance 9,694,761 F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: LTEST is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | Direct | 5,940,677 |
Reported balance
After 2022-12-14 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-12-14 · Other · Disposed 3,754,084 · Balance 5,940,677 F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F4: LFLU is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | Direct | 767,651 |
Reported balance
After 2022-12-14 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2022-12-14 · Other · Disposed 5,173,026 · Balance 767,651 F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F6: LCOVD is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | Direct | 32,176 |
Reported balance
After 2022-12-14 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2022-12-14 · Other · Disposed 735,475 · Balance 32,176 F7: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F8: SAFE is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 288,918 |
Reported balance
After 2022-12-14 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-12-14 · Other · Acquired 256,742 · Balance 288,918 F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F9: The shares are held directly by Chad Boeding (2,941), a trust of which Mr. Boeding is the trustee and beneficial owner (161,949 shares), and a limited liability company of which Mr. Boeding is the managing member (91,852 shares). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,014,593 |
Reported balance
After 2022-12-14 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2022-12-14 · Other · Acquired 725,675 · Balance 1,014,593 F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F7: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F10: The shares are held by entities under control of EPIQ Capital Group, LLC ("EPIQ"). None of the reporting persons has any pecuniary interest in these shares. F11: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. EPIQ, LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2: LTEST is the direct beneficial owner of these shares.
F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act.
F4: LFLU is the direct beneficial owner of these shares.
F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act.
F6: LCOVD is the direct beneficial owner of these shares.
F7: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act.
F8: SAFE is the direct beneficial owner of these shares.
F9: The shares are held directly by Chad Boeding (2,941), a trust of which Mr. Boeding is the trustee and beneficial owner (161,949 shares), and a limited liability company of which Mr. Boeding is the managing member (91,852 shares).
F10: The shares are held by entities under control of EPIQ Capital Group, LLC ("EPIQ"). None of the reporting persons has any pecuniary interest in these shares.
F11: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. EPIQ, LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Quince Therapeutics, Inc.
Report date December 31, 2020 · Filed February 01, 2021
Jointly reported with EPIQ Capital Group, LLC
Section 16 reporting ended · disclosed 2021-02-01. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2023 Filed Dec 29, 2023 17:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | OtherCommon Stock | 293,278 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-23-000513 · ownership.xml · nonDerivative · entry 4 EPIQ Capital Group, LLC · CIK 0001779453 · Managing Member of 10% Owner Boeding Chad · CIK 0001779451 · CEO of Managing Member EPQ LLC AMT PS · CIK 0001751796 · Owner EPQ LLC, AMTB PS · CIK 0001788890 · owner EPQ LLC, AMTC PS · CIK 0001814486 · owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F5 · shares: Chad Boeding is the owner of these shares through a trust that he controls. F9 · price: Upon consummation of the Merger, Chad Boeding received Transaction Consideration of 39,036 shares of Cyclo common stock. F10 · ownership.nature: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 17:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | OtherCommon Stock | 2,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-23-000513 · ownership.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · Managing Member of 10% Owner Boeding Chad · CIK 0001779451 · CEO of Managing Member EPQ LLC AMT PS · CIK 0001751796 · Owner EPQ LLC, AMTB PS · CIK 0001788890 · owner EPQ LLC, AMTC PS · CIK 0001814486 · owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 293,278 F1 · kind: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F4 · shares: EPQ LLC, AMTC PS is the direct owner of these shares. F8 · price: Upon consummation of the Merger, EPQ LLC, AMTC PS received Transaction Consideration of 332,750 shares of Cyclo common stock. F10 · ownership.nature: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 17:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | OtherCommon Stock | 3,394,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-23-000513 · ownership.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · Managing Member of 10% Owner Boeding Chad · CIK 0001779451 · CEO of Managing Member EPQ LLC AMT PS · CIK 0001751796 · Owner EPQ LLC, AMTB PS · CIK 0001788890 · owner EPQ LLC, AMTC PS · CIK 0001814486 · owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,793,278 F1 · kind: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F3 · shares: EPQ LLC, AMTB PS is the direct owner of these shares. F7 · price: Upon consummation of the Merger, EPQ LLC, AMTB PS received Transaction Consideration of 451,868 shares of Cyclo common stock. F10 · ownership.nature: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 17:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | OtherCommon Stock | 2,149,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-23-000513 · ownership.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · Managing Member of 10% Owner Boeding Chad · CIK 0001779451 · CEO of Managing Member EPQ LLC AMT PS · CIK 0001751796 · Owner EPQ LLC, AMTB PS · CIK 0001788890 · owner EPQ LLC, AMTC PS · CIK 0001814486 · owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,188,226 F1 · kind: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F2 · shares: EPQ LLC, AMT PS is the direct owner of these shares. F6 · price: Upon consummation of the Merger, EPQ LLC, AMT PS received Transaction Consideration of 286,071 shares of Cyclo common stock. F10 · ownership.nature: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:38 UTC | Lucira Health, Inc. LHDX · Entity 115613 | OtherCommon Stock | 725,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-22-000447 · s202212lhdxform4.xml · nonDerivative · entry 6 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LTEST PS · CIK 0001841495 · Less than 10% Owner EPQ LLC, LFLU PS · CIK 0001798799 · Less than 10% owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · Less than 10% owner Boeding Chad · CIK 0001779451 · CEO of 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,014,593 F1 · kind: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · kind: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5 · kind: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F7 · kind: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F1 · price: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5 · price: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F7 · price: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F10 · ownership.direct: The shares are held by entities under control of EPIQ Capital Group, LLC ("EPIQ"). None of the reporting persons has any pecuniary interest in these shares. F11 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. EPIQ, LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. F10 · ownership.nature: The shares are held by entities under control of EPIQ Capital Group, LLC ("EPIQ"). None of the reporting persons has any pecuniary interest in these shares. F11 · ownership.nature: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. EPIQ, LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:38 UTC | Lucira Health, Inc. LHDX · Entity 115613 | OtherCommon Stock | 256,742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-22-000447 · s202212lhdxform4.xml · nonDerivative · entry 5 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LTEST PS · CIK 0001841495 · Less than 10% Owner EPQ LLC, LFLU PS · CIK 0001798799 · Less than 10% owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · Less than 10% owner Boeding Chad · CIK 0001779451 · CEO of 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 288,918 F1 · kind: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · kind: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5 · kind: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F1 · price: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5 · price: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F9 · ownership.direct: The shares are held directly by Chad Boeding (2,941), a trust of which Mr. Boeding is the trustee and beneficial owner (161,949 shares), and a limited liability company of which Mr. Boeding is the managing member (91,852 shares). F9 · ownership.nature: The shares are held directly by Chad Boeding (2,941), a trust of which Mr. Boeding is the trustee and beneficial owner (161,949 shares), and a limited liability company of which Mr. Boeding is the managing member (91,852 shares). Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:38 UTC | Lucira Health, Inc. LHDX · Entity 115613 | OtherCommon Stock | 735,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-22-000447 · s202212lhdxform4.xml · nonDerivative · entry 4 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LTEST PS · CIK 0001841495 · Less than 10% Owner EPQ LLC, LFLU PS · CIK 0001798799 · Less than 10% owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · Less than 10% owner Boeding Chad · CIK 0001779451 · CEO of 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,176 F7 · kind: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F7 · price: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F8 · ownership.direct: SAFE is the direct beneficial owner of these shares. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:38 UTC | Lucira Health, Inc. LHDX · Entity 115613 | OtherCommon Stock | 5,173,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-22-000447 · s202212lhdxform4.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LTEST PS · CIK 0001841495 · Less than 10% Owner EPQ LLC, LFLU PS · CIK 0001798799 · Less than 10% owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · Less than 10% owner Boeding Chad · CIK 0001779451 · CEO of 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767,651 F5 · kind: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5 · price: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F6 · ownership.direct: LCOVD is the direct beneficial owner of these shares. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:38 UTC | Lucira Health, Inc. LHDX · Entity 115613 | OtherCommon Stock | 3,754,084 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-22-000447 · s202212lhdxform4.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LTEST PS · CIK 0001841495 · Less than 10% Owner EPQ LLC, LFLU PS · CIK 0001798799 · Less than 10% owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · Less than 10% owner Boeding Chad · CIK 0001779451 · CEO of 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,940,677 F3 · kind: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F3 · price: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F4 · ownership.direct: LFLU is the direct beneficial owner of these shares. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:38 UTC | Lucira Health, Inc. LHDX · Entity 115613 | OtherCommon Stock | 3,461,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001667731-22-000447 · s202212lhdxform4.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LTEST PS · CIK 0001841495 · Less than 10% Owner EPQ LLC, LFLU PS · CIK 0001798799 · Less than 10% owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · Less than 10% owner Boeding Chad · CIK 0001779451 · CEO of 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,694,761 F1 · kind: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F1 · price: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · ownership.direct: LTEST is the direct beneficial owner of these shares. Read SEC document |
| May 13, 2022 Filed May 16, 2022 17:49 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | PurchaseCommon Stock | 29,763 | $4.17 | $124,123.62 |
DisclosureSEC source: 0001667731-22-000196 · s202205epiqamti.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · Managing Member of 10% Owner EPQ LLC AMT PS · CIK 0001751796 · Owner EPQ LLC, AMTB PS · CIK 0001788890 · Owner EPQ LLC, AMTC PS · CIK 0001814486 · Owner Boeding Chad · CIK 0001779451 · CEO of Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,337,518 F1 · ownership.nature: Chad Boeding acquired the shares listed in column 4 through a trust that he controls. F2 · ownership.nature: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. EPQ LLC, AMT PS directly owns 2,149,292 common shares. EPQ LLC, AMTB PS directly owns 3,394,948 common shares. EPQ LLC, AMTC PS directly owns 2,500,000 common shares. Chad Boeding owns 293,278 common shares through a trust that he controls. Read SEC document |
| May 12, 2022 Filed May 16, 2022 17:49 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | PurchaseCommon Stock | 32,380 | $3.88 | $125,634.40 |
DisclosureSEC source: 0001667731-22-000196 · s202205epiqamti.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · Managing Member of 10% Owner EPQ LLC AMT PS · CIK 0001751796 · Owner EPQ LLC, AMTB PS · CIK 0001788890 · Owner EPQ LLC, AMTC PS · CIK 0001814486 · Owner Boeding Chad · CIK 0001779451 · CEO of Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,307,755 F1 · ownership.nature: Chad Boeding acquired the shares listed in column 4 through a trust that he controls. F2 · ownership.nature: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. EPQ LLC, AMT PS directly owns 2,149,292 common shares. EPQ LLC, AMTB PS directly owns 3,394,948 common shares. EPQ LLC, AMTC PS directly owns 2,500,000 common shares. Chad Boeding owns 293,278 common shares through a trust that he controls. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | Conversion2020B Convertible Promissory Note · Derivative | 735,475 | $17.00 | $12,503,075.00 |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · derivative · entry 9 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 735,475 shares Expires 2022-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The convertible promissory note automatically converted into shares of the Issuer's Common Stock upon the closing of the IPO. F2 · price: The convertible promissory note automatically converted into shares of the Issuer's Common Stock upon the closing of the IPO. F2 · derivative.exercise_date: The convertible promissory note automatically converted into shares of the Issuer's Common Stock upon the closing of the IPO. F6 · ownership.direct: EPQ LLC, LCOVD SAFE PS ("SAFE") is the direct beneficial owner of this shares. F8 · ownership.direct: EPIQ Capital Group, LLC ("EPIQ") may be deemed an indirect beneficial owner of 13,124,349 shares of Issuer's Common Stock, which are held by LFLU (3,754,084 shares), LCOVD (5,173,026 shares), SAFE (735,475 shares), and LTEST (3,461,764 shares). F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionSeries C Convertible Preferred · Derivative | 5,173,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · derivative · entry 8 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,173,026 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F5 · ownership.direct: EPQ LLC, LCOVD PS ("LCOVD") is the direct beneficial owner of these shares. F8 · ownership.direct: EPIQ Capital Group, LLC ("EPIQ") may be deemed an indirect beneficial owner of 13,124,349 shares of Issuer's Common Stock, which are held by LFLU (3,754,084 shares), LCOVD (5,173,026 shares), SAFE (735,475 shares), and LTEST (3,461,764 shares). F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionSeries B Convertible Preferred · Derivative | 3,754,084 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · derivative · entry 7 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,754,084 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F4 · ownership.direct: EPQ LLC, LFLU PS ("LFLU") is the direct beneficial owner of these shares. F8 · ownership.direct: EPIQ Capital Group, LLC ("EPIQ") may be deemed an indirect beneficial owner of 13,124,349 shares of Issuer's Common Stock, which are held by LFLU (3,754,084 shares), LCOVD (5,173,026 shares), SAFE (735,475 shares), and LTEST (3,461,764 shares). F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionSeries B Convertible Preferred · Derivative | 32,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · derivative · entry 6 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.direct: Chad Boeding is the beneficial owner of these shares through a trust that he controls. F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | PurchaseCommon Stock | 3,461,764 | $17.00 | $58,849,988.00 |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · nonDerivative · entry 5 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,461,764 F7 · ownership.direct: EPQ LLC, LTEST PS ("LTEST") is the direct beneficial owner of these shares. F8 · ownership.direct: EPIQ Capital Group, LLC ("EPIQ") may be deemed an indirect beneficial owner of 13,124,349 shares of Issuer's Common Stock, which are held by LFLU (3,754,084 shares), LCOVD (5,173,026 shares), SAFE (735,475 shares), and LTEST (3,461,764 shares). F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionCommon Stock | 735,475 | $17.00 | $12,503,075.00 |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · nonDerivative · entry 4 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The convertible promissory note automatically converted into shares of the Issuer's Common Stock upon the closing of the IPO. F6 · ownership.direct: EPQ LLC, LCOVD SAFE PS ("SAFE") is the direct beneficial owner of this shares. F8 · ownership.direct: EPIQ Capital Group, LLC ("EPIQ") may be deemed an indirect beneficial owner of 13,124,349 shares of Issuer's Common Stock, which are held by LFLU (3,754,084 shares), LCOVD (5,173,026 shares), SAFE (735,475 shares), and LTEST (3,461,764 shares). F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionCommon Stock | 5,173,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,173,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F5 · ownership.direct: EPQ LLC, LCOVD PS ("LCOVD") is the direct beneficial owner of these shares. F8 · ownership.direct: EPIQ Capital Group, LLC ("EPIQ") may be deemed an indirect beneficial owner of 13,124,349 shares of Issuer's Common Stock, which are held by LFLU (3,754,084 shares), LCOVD (5,173,026 shares), SAFE (735,475 shares), and LTEST (3,461,764 shares). F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionCommon Stock | 3,754,084 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,754,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F4 · ownership.direct: EPQ LLC, LFLU PS ("LFLU") is the direct beneficial owner of these shares. F8 · ownership.direct: EPIQ Capital Group, LLC ("EPIQ") may be deemed an indirect beneficial owner of 13,124,349 shares of Issuer's Common Stock, which are held by LFLU (3,754,084 shares), LCOVD (5,173,026 shares), SAFE (735,475 shares), and LTEST (3,461,764 shares). F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 18:39 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionCommon Stock | 32,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001779453-21-000004 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · 10% owner EPQ LLC, LFLU PS · CIK 0001798799 · <10% Owner EPQ LLC, LCOVD PS · CIK 0001818376 · 10% owner EPQ LLC, LCOVD SAFE PS · CIK 0001833912 · <10% Owner EPQ LLC, LTEST PS · CIK 0001841495 · <10% Owner Boeding Chad · CIK 0001779451 · CEO of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F3 · ownership.direct: Chad Boeding is the beneficial owner of these shares through a trust that he controls. F9 · ownership.direct: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 18:55 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 2,440 | $44.06 | $107,506.40 |
DisclosureSEC source: 0001779453-20-000005 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% Owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of the Boeding Family Trust Disclosed balance after: 2,860,967 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own more than 10% of the common stock of the issuer. Mr. Boeding is the Manager of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group. CTYM, CTEPQ and Mr. Boeding disclaims beneficial ownership of the shares reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 18:55 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 6,600 | $44.32 | $292,512.00 |
DisclosureSEC source: 0001779453-20-000005 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% Owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of the Boeding Family Trust Disclosed balance after: 2,858,527 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own more than 10% of the common stock of the issuer. Mr. Boeding is the Manager of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group. CTYM, CTEPQ and Mr. Boeding disclaims beneficial ownership of the shares reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| May 22, 2020 Filed May 22, 2020 18:03 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 2,085 | $55.90 | $116,551.50 |
DisclosureSEC source: 0001779453-20-000002 · primary_doc.xml · nonDerivative · entry 4 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% Owne Boeding Chad · CIK 0001779451 · Managing Member of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee for the Boeding Family Trust Disclosed balance after: 2,851,927 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 21, 2020 Filed May 22, 2020 18:03 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 520 | $55.80 | $29,016.00 |
DisclosureSEC source: 0001779453-20-000002 · primary_doc.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% Owne Boeding Chad · CIK 0001779451 · Managing Member of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee for the Boeding Family Trust Disclosed balance after: 2,849,842 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:03 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 417 | $57.22 | $23,860.74 |
DisclosureSEC source: 0001779453-20-000002 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% Owne Boeding Chad · CIK 0001779451 · Managing Member of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee for the Boeding Family Trust Disclosed balance after: 2,849,322 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:03 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 5,668 | $58.00 | $328,744.00 |
DisclosureSEC source: 0001779453-20-000002 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% Owne Boeding Chad · CIK 0001779451 · Managing Member of 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee for the Boeding Family Trust Disclosed balance after: 2,848,905 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 13:40 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | OtherCommon Stock | 4,338 | $54.30 | $235,553.40 |
DisclosureSEC source: 0001779453-20-000001 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% Owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee for the Mitsou Peterson-Cushing 2019 Irrevocable Trust Disclosed balance after: 2,843,237 F1 · kind: Shares were distributed in kind to the beneficiary of the Trust. F3 · price: Shares distributed in kind. Reported price is the average of the high and low price for the day. F2 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 21, 2019 Filed Aug 21, 2019 16:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 1,635 | $24.87 | $40,660.00 |
DisclosureSEC source: 0001779453-19-000003 · primary_doc.xml · nonDerivative · entry 4 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · Managing Member of IA Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,834,561 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
| August 21, 2019 Filed Aug 21, 2019 16:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 420 | $24.87 | $10,444.77 |
DisclosureSEC source: 0001779453-19-000003 · primary_doc.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · Managing Member of IA Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,832,926 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 21, 2019 Filed Nov 29, 2019 13:07 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 1,635 | $24.87 | $40,660.00 |
DisclosureSEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 4 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,847,575 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
| August 21, 2019 Filed Nov 29, 2019 13:07 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 420 | $24.87 | $10,444.77 |
DisclosureSEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,845,940 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 16:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 2,310 | $25.69 | $59,343.90 |
DisclosureSEC source: 0001779453-19-000003 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · Managing Member of IA Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832,506 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 16:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 600 | $25.69 | $15,414.00 |
DisclosureSEC source: 0001779453-19-000003 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · Managing Member of IA Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee for Boeding Family Trust Disclosed balance after: 2,830,196 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 20, 2019 Filed Nov 29, 2019 13:07 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 2,310 | $25.69 | $59,343.90 |
DisclosureSEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,845,520 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
| August 20, 2019 Filed Nov 29, 2019 13:07 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 600 | $25.69 | $15,414.00 |
DisclosureSEC source: 0001779453-19-000007 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee for Boeding Family Trust Disclosed balance after: 2,843,210 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/21/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 19, 2019 Filed Aug 19, 2019 17:10 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 2,100 | $26.50 | $55,639.92 |
DisclosureSEC source: 0001779451-19-000001 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · Managing Member of IA Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,829,596 F1 · ownership.direct: 1 The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 19, 2019 Filed Nov 29, 2019 12:59 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 2,100 | $26.50 | $55,639.92 |
DisclosureSEC source: 0001779453-19-000006 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,842,610 F2 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/19/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 17:10 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 700 | $26.37 | $18,459.98 |
DisclosureSEC source: 0001779451-19-000001 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · Managing Member of IA Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,827,496 F1 · ownership.direct: 1 The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 16, 2019 Filed Nov 29, 2019 12:59 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 700 | $26.37 | $18,459.98 |
DisclosureSEC source: 0001779453-19-000006 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,840,510 F2 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 8/19/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2019 Filed Jun 14, 2019 12:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 80 | $27.05 | $2,164.00 |
DisclosureSEC source: 0001779453-19-000002 · primary_doc.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as custodian for minor child Disclosed balance after: 2,826,796 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 3 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2019 Filed Jun 14, 2019 12:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,170 | $27.58 | $115,008.60 |
DisclosureSEC source: 0001779453-19-000002 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,826,716 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 3 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2019 Filed Jun 14, 2019 12:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,350 | $26.41 | $114,883.50 |
DisclosureSEC source: 0001779453-19-000002 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,822,546 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 3 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
| May 10, 2019 Filed Nov 29, 2019 12:52 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 80 | $27.05 | $2,164.00 |
DisclosureSEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as custodian for minor child Disclosed balance after: 2,839,810 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2019 Filed Nov 29, 2019 12:52 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,170 | $27.58 | $115,008.60 |
DisclosureSEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,839,730 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2019 Filed Nov 29, 2019 12:52 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,350 | $26.41 | $114,883.50 |
DisclosureSEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,835,560 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.